Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement and research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. The preclinical program […]
Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company specializing in clinically documented probiotics. The acquisition […]
Pendulum Therapeutics, a cutting-edge microbiome company dedicated to making people healthier through microbiome-targeted solutions, announced today the launch of Pendulum Glucose Control, the first and only medical probiotic clinically shown to lower A1C and blood sugar […]
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and other […]
Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new University of Copenhagen […]
Abstract: At Eagle Genomics, we use graph databases to model the biological domain. This enables the scientist to access the relevant information and insight they are looking for in a number of industries, including pharmaceuticals, healthcare […]
Abstract: As vast amounts of high-throughput data are generated from sequencing the microbiome, suitable analysis approaches are needed to effectively evaluate the data and reach robust conclusions to power studies incorporating microbiome research questions. Sequencing […]
Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set […]
Intralytix, Inc. announced that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy […]
Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]
The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]